Member Info for Burble

Post has now been deleted....

'As for the AACR etc, I think we will see the company demonstrating that they now know the genetic settings in which their treatment works best…..'

Not long to wait I guess, given that the presentation is less than two weeks away from the AACR poster.

They did say at the AGM when they announced news, they would be announcing it across all platforms. They weren’t joking were they?!

EE

Technically yes. But it’s never going to happen. You’d have to vaccinate against every possible cancer on the anssumption you’d stop them and that’s never going to happen. It will be used like any other vaccine, you have a diagnosis and then you get treated. Otherwise, costs would be astronomical.

‘Burble, we’ve vaccinated you against melanoma. Go enjoy life.’

Some time later. ‘Burble I’m sorry, but you have pancreatic cancer.’

However, arguing the other side of the coin. Having said that Modi-1/2 if high avidity and long lasting enough, I could see possibly working in this manner because it’s not specifically tailored to an individual cancer epitope, more the fundamental biochemical process that cancer cells rely on (autophagy).

I sincerely hope not. This constant repeat of one data is going on ad nauseam

Berm I would assume that the use of the words 'such as' in the patent application mean this is broader than just Ipi/Nivo, and instead would cover any CPI in the PD-1i and CTLA-4i space. As such, would cover second generation CPIs as well as biosimilars.

April 25, 2024: Late-Breaking and Clinical Trials Abstract Texts Posted to Online Itinerary Planner and Meeting App (12:00 p.m. CT) and Published in an Online-only Supplement to Cancer Research

Great spot Berm, and late breaking is good as well - means we should get the most upto date datasets

Sad to hear you've sold out Bojo, your research here was great.

I don't blame you in the slightest, the markets at the moment are not great for many. I note that on the other side even Inan has suddenly gone quiet.

As with all biotech, it is a balancing act between risk and reward. I'm still holding on here, but even this is testing my appetite. I agree with you, there is now a real risk of the company being taken private or needing another raise.

Berm/CW

That makes sense.

I guess my big worry is trial delays and additional costs. Imagine getting halfway through recruitment and dosing of patients and then having the rug pulled from underneath you. The financial cost and impact on the trial would be colossal.

Whilst I appreciate time has been invested in scouting out potential sites, it would be interesting to be a fly on the wall as to whether SCLP have risk mitigation in place or whether they may look elsewhere.

Interestingly, the fact that melanoma has the biggest incidence rates in Australia may make it attractive - especially if there were some incentives to fund research there. One of the conversations I know many are having across the UK and Europe is ‘how can we capitalise on what’s going on in the US for our own benefit’ - I’m sure these counties aren’t alone in this thinking.

So maybe actually the read out being later in the year for the SCOPE trial may help us make those difficult decisions as to what comes next. Rather than be in a situation where we had started and then had to pivot

In many of the conversations I’ve been having at work, geopolitics has come up a lot. Especially with regard to medicines, vaccines and clinical trials and what is going on within the US.

We are seeing oncology patients on trials in the US learning their treatment has been cancelled midway through due to NIH funding cuts.

I’m curious whether any planned SCOPE registration trial will be run in the US, or whether there will be a shift away from this to other locations around the globe - especially given RFK’s outspoken anti-vaccine beliefs.

I wonder whether we will get notification of arms of the SCOPE trial being fully recruited.

The AACR IO poster is now on the website. It’s frustrating that a number of us had to chase. It should be automatic - JC is presenting at X time, within 24 hours the poster should be uploaded. Doesn’t take a lot to think and plan ahead.

https://scancell.co.uk/wp-content/uploads/2025/03/AACR-IO-2025-TCR-poster-Final.pdf#new_tab

CW if you can send me a copy I would be very grateful. Email address is - stupors_genii.9m@icloud.com

I sent the commercial enquiries email a message and received nothing back.

So you’re one step ahead of me if you have the poster!

The talk on the 'development & Qualification Of A Cell-Based Potency Assay For Two Novel DNA Cancer Vaccines, showing how Scancell has developed a novel and qualifiable cell-based potency assay to detected and measure the potency of the iSCIB1+ DNA vaccine.' sounds fascinating. Would love to sit in on this one.

Cleaner - 'just thinking aloud could the Glymab platform more effective with their Duobody platform , so ditching CD38 to advance Glymabs in the clinic'

If I'm honest, I think this is wishful thinking here.

Ditching the CD38 will be a commercial decision based on the data from this trial. The glymabs are directed against a completely different target, so whilst they may be looking at their pipeline and identifying more promising leads, in my opinion I don't think the two decisions are mutually linked especially given we have not heard a peep from Genmab about the progress of the glymabs they have licenced and how they're performing in the lab/pre-clinical.

Until we here concrete news directly linking Genmab and Scancell, I would assume that any other Genmab news is just that - genmab news. Not Scancell news.

I used the website contact function last week to ask when we can expect the AACR IO poster to be uploaded to the website. The form submitted, but I've not heard anything back.

Does any one have an upto date email address for the company and either pass it on here or contact them to ask?

Add to this the fact there is the second anomaly further north...

There was a brief positive update last week, unsure whether that's what has been picked up by Google alerts.